Evidence map›Paper›PMID 36983128›Full record

ArticleJournal of clinical medicine2023

Analysis of a Combined HBHA and ESAT-6-Interferon-γ-Release Assay for the Diagnosis of Tuberculous Lymphadenopathies.

Françoise Mascart, Maya Hites, Emmanuelle Watelet, Gil Verschelden, Christelle Meuris, Jean-Luc Doyen, Anne Van Praet, Audrey Godefroid, Emmanuelle Petit, Mahavir Singh and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Françoise MascartLaboratory of Vaccinology and Mucosal Immunity, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium.ORCID 0000-0001-7635-7944
Maya HitesClinic of Infectious and Tropical Diseases, Hôpital Universitaire de Bruxelles (HUB)-Hôpital Erasme, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium.ORCID 0000-0001-6961-6039
Emmanuelle WateletDepartment of Pneumology, Clinique St-Anne/St-Remi-Chirec, 1070 Brussels, Belgium.
Gil VerscheldenDepartment of Internal Medicine, Universitair Ziekenhuis Brussel-UZ Brussel, Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium.ORCID 0000-0002-5856-3143
Christelle MeurisDepartment of Infectious Diseases, Liège University Hospital, 4000 Liège, Belgium.
Jean-Luc DoyenDepartment of Pneumology, Clinique St-Anne/St-Remi-Chirec, 1070 Brussels, Belgium.
Anne Van PraetLaboratory of Vaccinology and Mucosal Immunity, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium.
Audrey GodefroidLaboratory of Vaccinology and Mucosal Immunity, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium.
Emmanuelle PetitU-1019-UMR8204, Center for Infection and Immunity of Lille (CIIL), CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, University of Lille, 59000 Lille, France.
Mahavir SinghLionex Diagnostics and Therapeutics, 38126 Braunschweig, Germany.
Camille LochtU-1019-UMR8204, Center for Infection and Immunity of Lille (CIIL), CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, University of Lille, 59000 Lille, France.ORCID 0000-0001-7295-7336
Véronique CorbièreLaboratory of Vaccinology and Mucosal Immunity, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium.
Université Libre de Bruxelles · BECentre National de la Recherche Scientifique · FRClinique Saint-Joseph · BELionex (Germany) · DEUniversity of Liège · BEVrije Universiteit Brussel · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesThe incidence of tuberculosis lymphadenopathy (TBLA) is increasing, and diagnostic procedures lack sensitivity and are often highly invasive. TBLA may be asymptomatic, and differential diagnosis with other adenopathies (ADPs) is difficult. We evaluated a blood-cell interferon-γ release assay (IGRA) with two different stage-specific mycobacterial antigens for the differential diagnosis of ADP suspected of mycobacterial origin.

methodsTwenty-one patients were included and divided into three groups: (1) cervical/axillar ADP (

resultsAn IGRA profile highly suggestive of active TB (higher IFN-γ response to ESAT-6 compared to HBHA) was found for 3/6 TBLA patients from group 1, and for all the TBLA patients from groups 2 and 3, whereas this profile was not noticed in patients with a final alternative diagnosis.

conclusionThese results highlight the potential value of this combined HBHA/ESAT-6 IGRA as a triage test for the differential diagnosis of ADP.

Indexed as

ESAT-6HBHAIGRAtuberculous lymphadenopathy

Identifiers

PMID36983128
PMCPMC10052338
OpenAlexW4323667739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.